ArticleEsophagus : official journal of the Japan Esophageal Society2025
Rikkunshito attenuates nutritional decline and skeletal muscle loss during preoperative chemotherapy for esophageal cancer.
Article in Esophagus : official journal of the Japan Esophageal Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRikkunshito is a traditional Japanese herbal medicine known to alleviate chemotherapy-induced gastrointestinal symptoms. However, the clinical impact of rikkunshito on patients undergoing neoadjuvant or conversion chemotherapy followed by curative surgery for esophageal cancer remains unclear.
methodsWe analyzed 57 patients with esophageal cancer who underwent curative surgery with preoperative chemotherapy between April 2021 and December 2024. Patients who did and did not receive rikkunshito during chemotherapy were assigned to the rikkunshito and control groups, respectively. Nutritional status was evaluated using albumin levels, lymphocyte counts, prognostic nutritional index, geriatric nutritional risk index, body weight, and body mass index (BMI), and skeletal muscle area (SMA) at L3 before and after chemotherapy. Propensity score matching (PSM) based on baseline characteristics, including age, sex, initial BMI, clinical stage, chemotherapy regimen, and initial PNI and SMA was performed.
resultsOverall, the rikkunshito group showed significantly lower rates of body weight (p = 0.016) and BMI loss (p = 0.011) than controls. Although SMA reduction did not reach statistical significance, a trend toward preservation was observed (p = 0.093). After PSM (n = 16 per group), the rikkunshito group showed a significantly lower reduction in body weight (p = 0.031), BMI (p = 0.016), and SMA (p < 0.001).
conclusionsRikkunshito administration during preoperative chemotherapy for esophageal cancer was associated with better preservation of body composition, including skeletal muscle mass. This suggests the potential role of rikkunshito as a supportive therapy to mitigate sarcopenia and nutritional decline during intensive treatment of esophageal cancer.
Indexed as
Identifiers
40890470What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.